Drugs / SEN0014196
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01485965 | Nov 2011 → Nov 2012 | Huntington disease | Siena Biotech S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT01485952 | Mar → Nov 2011 | Huntington disease | Siena Biotech S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT01521832 | Oct 2009 → May 2010 | Huntington disease | Siena Biotech S.p.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01521585 | Nov 2011 → Oct 2012 | Huntington disease | Siena Biotech S.p.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEN0014196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01485965 ↗ |
| Known as | selisistat | “Selisistat (SEN0014196), a first-in-class SirT1 inhibitor, is being developed as a disease-modifying therapy for Huntington's disease.” PMID 25223836 ↗ Mar 2015 |
| Action | Inhibit | “a first-in-class SirT1 inhibitor” PMID 25223836 ↗ Mar 2015 |
| Route | Oral | “Multiple Oral Doses of SEN0014196” NCT01485952 ↗ |